Prelude Capital Management, LLC Sellas Life Sciences Group, Inc. Transaction History
Prelude Capital Management, LLC
- $1.85 Billion
- Q1 2024
Shares
2 transactions
Others Institutions Holding SLS
# of Institutions
35Shares Held
8.03MCall Options Held
2.52MPut Options Held
24.7K-
Anson Funds Management LP Dallas, TX4.83MShares$5.41 Million0.8% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.51MShares$1.69 Million0.0% of portfolio
-
Empery Asset Management, LP New York, NY308KShares$345,4813.71% of portfolio
-
Black Rock Inc. New York, NY278KShares$311,6040.0% of portfolio
-
Geode Capital Management, LLC Boston, MA273KShares$305,8300.0% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $23M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...